Advanced Drug Delivery Systems: New Developments, New Technologies
The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011.
The largest sector of the market consists of sustained release/implants/transdermal drug delivery systems, with more than 50% of the total U.S. market in 2005. Through the forecast period this sector will gradually give way to targeted drug delivery systems, which should control almost 48% of the market in 2011.
Targeted drug delivery has the highest growth rate, with a 23.3% AAGR through 2011. The next highest are transmucosal drug delivery systems, with 15.3%.
The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.
This is a very complex market, where many technologies are combined to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained release oral/injectable drug delivery market is a good example.
Pegylation, nanoparticles, polymers and liposomes are significant new markets. These technologies combined together could be a multibillion dollar global market in the next few years.
Acquisition strategies and collaborations by companies are also covered in this report, e.g., the acquisition of Guilford Pharmaceuticals by MGI Pharma, which added Gliadel Wafer (polifeprosan 20 with carmustine implant) to its portfolio. This study also discusses the strengths and weaknesses of the drug development market in light of new technologies, growing competition and changing customer needs.
SCOPE OF STUDY
This report contains:
- An overview of the major types of drug delivery systems used in the health industry
- Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
- Discussion of the technological issues, including the latest trends and developments
- Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
- Profiles of the major players within the industry and a detailed patent analysis.
A comprehensive literature and patent search was conducted. The literature included technical newsletters and journals, as well as many other sources. The data were collected through interviews with leading pharmaceutical and biotech sources. Projections were based on estimates of the current number of end users, potential end users, likely unit prices, rates of consumption and othermarket trends.
BCC surveyed many companies to obtain data for this study. We spoke with officials and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and from government sources.
ABOUT THE AUTHOR
Shalini Shahani is a young and enterprising scientist and holds a Masters degree in Pharmaceutical Chemistry. Among the research topics she has covered are: Studies on Compounds of Potential and Pharmaceutical Interest from Ibuprofen and 2-Naphthyl Acetic acid. Shahani was awarded a Gold medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are "Medical Imaging Reagents," "Orthopedic Drugs, Implants & Devices," "Reagents of Chromatography", "Spectroscopy, an Enduring Market" and "Advanced Drug Delivery Systems".
- The U.S. market for drug delivery systems in 2002 was $38.8 billion, and is expected to rise at an average annual growth rate (AAGR) of 11.3% and reach $74.5 billion by 2008.
- The sustained release (oral, injectable and topical) dosage form market is rising at an AAGR of 9.7% is expected to reach $34.1 billion by 2008.
- The transmucosal market is expected to grow at an AAGR of 12.8% and reach $17.7 billion by 2008.
- The market for targeted delivery systems was $7.3 billion in 2002 and will reach $15.5 billion by 2008.
- Transdermal systems and implants and IUDs are expected to climb at AAGRs of 11.1% and 12.4%, respectively.
- Despite the complaints of health care being too expensive, the U.S. pharmaceutical industry is expected to offer increasing opportunities for advanced drug delivery systems, with the U.S. market for the systems estimated at $16.3 billion in 2000. The efficacy, safety, and convenience of the technologies should maintain average annual growth of 10.9% over the next five years, when sales are predicted to be about $27.4 billion.
- At $13.8 billion in estimated 2000 manufacturers' sales, standard controlled release technologies (microencapsulation, polymer/membrane, and coatings) dominate the market for advanced drug delivery systems. The intense competition in generic products is stimulating growth (7.2%), especially in oral formats, both osmotic and microencapsulated. Demand for injected sustained release products is also spurring growth. The widespread interest in controlled released systems should result in sales reaching $19.6 billion in five years.